Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
about
Sequential versus combination chemotherapy for advanced colorectal cancerClinical management of localized colon cancer with capecitabineCapecitabine in the management of colorectal cancerThe clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancerRelationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study.Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases.Pharmacologic resistance in colorectal cancer: a reviewTherapeutic potential of TAS-102 in the treatment of gastrointestinal malignanciesCardiac effects of anticancer therapy in the elderlyEfficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysisManagement of locally advanced and metastatic colon cancer in elderly patientsIncidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trialsEvaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidinesDecision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer.Oral drugs in the treatment of metastatic colorectal cancer.Irinotecan-induced dysarthria.Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trialsAn individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer.Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist.Acute coronary syndrome induced by oral capecitabine.Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine.XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancerA phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer.Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: meta-analysis.Acute gout episodes during treatment with capecitabine: a case report.Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancerCapecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04Prospective phase II study of preoperative chemoradiation with capecitabine in locally advanced rectal cancerOxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.Efficacy, safety, and cost of new anticancer drugs. Pessimistic conclusion was not justified.Effect of a structured, active, home-based cancer-treatment program for the management of patients on oral chemotherapyCapecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancerA phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumorsMaintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinomaA phase I study of an oral simulated FOLFOX with high dose capecitabine.
P2860
Q24234461-A0E9A29B-53C8-4C7C-B938-469F7B6458ACQ24611758-FCFDD8DB-DAF9-4FBC-B7B4-703B35D2BAA8Q24633039-2D029184-FC09-4DCD-A9FC-7683D9616F42Q24652904-92FCEB53-0183-4DC9-A411-697B56441C4DQ25257445-FB05113F-42BC-4C9A-B06D-221D8EF00D69Q26752747-0D452DC5-D336-4FD8-A041-DCD9C9FA6F1AQ26769850-A88BC7C9-AE2A-46CF-BFB4-F7BF4005CE00Q26777679-A882220A-9938-48B5-B577-40673CB75450Q26863244-152F55E9-A2EE-4198-8218-DC7CC3E5687DQ26865057-4922E64B-07AB-4393-9434-FF07A90791FFQ27026129-A866A777-E4EE-4093-8A6D-5E2C82E3D2EEQ27028095-59C6D89A-E85D-4CCB-BD66-486165CDD6B1Q28534572-5BEDA6C1-2DFB-4F6F-960C-DBC1EEBF5CC2Q30244769-B517E289-4093-4A17-8CFE-F87644D42FB2Q30251387-932E56FD-7AAA-491C-B8C5-620A1E8215A1Q30470164-B6758A5E-CA80-4B75-BF78-A9B1313EE011Q30913489-7869D25E-1062-4A40-8067-067A36364B74Q31106341-C9995924-5D92-4532-A3C9-216C0369E4A8Q31168985-08DD7909-00DF-4D73-9671-11A46E39EEBDQ33235644-D85E1FD3-8DB0-47F1-A9D5-BA3EC0C45207Q33370303-F01CEAEE-4A89-4B68-9883-DC29E8F1CD16Q33370632-9425FE76-2BA5-4545-8A5B-82B566445178Q33370792-F3372C8D-26A7-4EE0-ADC6-8BBF44DC2790Q33376718-FA58F31A-84DB-4F94-8A64-AB53EF4B5880Q33399530-E181E5D4-BAD6-4D72-A450-20F3CDB8686AQ33425826-4BBD2C98-2FEF-424B-8D56-526452F10E7CQ33426732-BCCB3792-2C05-4872-8B26-36FA2282271BQ33429923-8B7F5C37-5D5F-43A0-8B0D-75078AD2FDD1Q33442681-C70C4B8E-2F71-4127-A5E6-AE501A1EDCAEQ33557272-5A035755-DC42-45BA-849E-477698B621B3Q33620052-7ABD1A16-2387-406A-B8FB-AE5AE5C8F19EQ33729092-1B109DD4-73F5-4BF1-8C5C-1D59D0E3CCF6Q33746816-3C236955-BA6F-44D1-82E9-1ACDF143B42FQ33747440-5C94A0B1-A3ED-4317-B5EA-CAD3FD775698Q33813161-769A44B6-FDDC-4406-ADCB-B86A635E9BCDQ33831232-DEAE680A-F0B2-49BA-B5C5-EFD7B11EB1EDQ33847848-13E6843C-E96B-49D7-B03D-81F9EC1FEE1BQ33919101-100DAE02-E059-4BF7-9F0F-A7F17C0793AAQ33967458-8799560E-5F1D-44D4-A81C-56D60B17C62FQ33973344-272CE396-074A-45BD-976F-1C7FE6D4EC4D
P2860
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Oral capecitabine compared wit ...... ts of a large phase III study.
@ast
Oral capecitabine compared wit ...... ts of a large phase III study.
@en
Oral capecitabine compared wit ...... ts of a large phase III study.
@en-gb
Oral capecitabine compared wit ...... ts of a large phase III study.
@nl
type
label
Oral capecitabine compared wit ...... ts of a large phase III study.
@ast
Oral capecitabine compared wit ...... ts of a large phase III study.
@en
Oral capecitabine compared wit ...... ts of a large phase III study.
@en-gb
Oral capecitabine compared wit ...... ts of a large phase III study.
@nl
prefLabel
Oral capecitabine compared wit ...... ts of a large phase III study.
@ast
Oral capecitabine compared wit ...... ts of a large phase III study.
@en
Oral capecitabine compared wit ...... ts of a large phase III study.
@en-gb
Oral capecitabine compared wit ...... ts of a large phase III study.
@nl
P2093
P1476
Oral capecitabine compared wit ...... ts of a large phase III study.
@en
P2093
B Osterwalder
E Van Cutsem
G Perez-Manga
J M Vieitez
P304
P356
10.1200/JCO.2001.19.21.4097
P407
P577
2001-11-01T00:00:00Z